Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: Association with Gag-specific CD8 T cell responses

Journal of Immunology

Volumn 182, Issue 12, 2009, Pages 7828-7837

  Sáez Cirión, Asier ^a   Sinet, Martine ^b,c   Shin, So Youn ^a   Urrutia, Alejandra ^b,c   Versmisse, Pierre ^a   Lacabaratz, Christine ^b,c   Boufassa, Faroudy ^d   Avettand Fènoël, Véronique ^e,f   Rouzioux, Christine ^e,f   Delfraissy, Jean François ^b,c,d   Barré Sinoussi, Françoise ^a   Lambotte, Olivier ^b,c,d   Venet, Alain ^b,c   Pancino, Gianfranco ^a  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d BICÊTRE HOSPITAL   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON;

ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CELL HETEROGENEITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE CONTROL; EX VIVO STUDY; FEMALE; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LENTIVIRINAE; MALE; PRIMATE; PRIORITY JOURNAL; VIREMIA; VIRUS REPLICATION; BIOSYNTHESIS; CELL CULTURE; ENZYMOLOGY; GENETIC HETEROGENEITY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; GENE PRODUCTS, GAG; GENETIC HETEROGENEITY; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; VIRUS REPLICATION;

EID: 67649213034     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803928     Document Type: Article

References (47)

1. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68: 6103-6110.
2. + T-cell responses are involved in durable control of AIDS virus replication. J. Virol. 81: 3465-3476.
3. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189: 991-998.
4. Flores-Villanueva, P. O., E. J. Yunis, J. C. Delgado, E. Vittinghoff, S. Buchbinder, J. Y. Leung, A. M. Uglialoro, O. P. Clavijo, E. S. Rosenberg, S. A. Kalams, et al. 2001. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc. Natl. Acad. Sci. USA 98: 5140-5145.
5. Kiepiela, P., A. J. Leslie, I. Honeyborne, D. Ramduth, C. Thobakgale, S. Chetty, P. Rathnavalu, C. Moore, K. J. Pfafferott, L. Hilton, et al. 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432: 769-775.
6. Migueles, S. A., M. S. Sabbaghian, W. L. Shupert, M. P. Bettinotti, F. M. Marincola, L. Martino, C. W. Hallahan, S. M. Selig, D. Schwartz, J. Sullivan, and M. Connors. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA 97: 2709-2714.
7. + T-cell responses to the Gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J. Virol. 76: 2298-2305.
8. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13: 46-53.
9. Riviere, Y., M. B. McChesney, F. Porrot, F. Tanneau-Salvadori, P. Sansonetti, O. Lopez, G. Pialoux, V. Feuillie, M. Mollereau, S. Chamaret, et al. 1995. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res. Hum. Retroviruses 11: 903-907.
10. Chopera, D. R., Z. Woodman, K. Mlisana, M. Mlotshwa, D. P. Martin, C. Seoighe, F. Treurnicht, D. A. de Rosa, W. Hide, S. A. Karim, et al. 2008. Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS Pathog. 4: e1000033.
11. Martinez-Picado, J., J. G. Prado, E. E. Fry, K. Pfafferott, A. Leslie, S. Chetty, C. Thobakgale, I. Honeyborne, H. Crawford, P. Matthews, et al. 2006. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80: 3617-3623.
12. Rousseau, C. M., M. G. Daniels, J. M. Carlson, C. Kadie, H. Crawford, A. Prendergast, P. Matthews, R. Payne, M. Rolland, D. N. Raugi, et al. 2008. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J. Virol. 82: 6434-6446.
13. Schneidewind, A., M. A. Brockman, R. Yang, R. I. Adam, B. Li, S. Le Gall, C. R. Rinaldo, S. L. Craggs, R. L. Allgaier, K. A. Power, et al. 2007. Escape from the dominant HLA-B27 restricted CTL response in Gag is associated with a dramatic reduction in HIV-1 replication. J. Virol. 81: 12382-12393.
14. Goepfert, P. A., W. Lumm, P. Farmer, P. Matthews, A. Prendergast, J. M. Carlson, C. A. Derdeyn, J. Tang, R. A. Kaslow, A. Bansal, et al. 2008. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J. Exp. Med. 205: 1009-1017.
15. Deeks, S. G., and B. D. Walker. 2007. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27: 406-416.
16. Saez-Cirion, A., G. Pancino, M. Sinet, A. Venet, and O. Lambotte. 2007. HIV controllers: how do they tame the virus? Trends Immunol. 28: 532-540.
17. Lambotte, O., F. Boufassa, Y. Madec, A. Nguyen, C. Goujard, L. Meyer, C. Rouzioux, A. Venet, and J. F. Delfraissy. 2005. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 41: 1053-1056.
18. Dinoso, J. B., S. Y. Kim, R. F. Siliciano, and J. N. Blankson. 2008. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin. Infect. Dis. 47: 102-104.
19. Bailey, J. R., K. G. Lassen, H. C. Yang, T. C. Quinn, S. C. Ray, J. N. Blankson, and R. F. Siliciano. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J. Virol. 80: 4758-4770.
20. Emu, B., E. Sinclair, H. Hatano, A. Ferre, B. Shacklett, J. N. Martin, J. M. McCune, and S. G. Deeks. 2008. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J. Virol. 82: 5398-5407.
21. Sáez-Cirión, A., C. Lacabaratz, O. Lambotte, P. Versmisse, A. Urrutia, F. Boufassa, F. Barre-Sinoussi, J. F. Delfraissy, M. Sinet, G. Pancino, and A. Venet. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar CTL activation phenotype. Proc. Natl. Acad. Sci. USA 104: 6776-6781.
22. Hatano, H., E. L. Delwart, P. J. Norris, T. H. Lee, J. Dunn-Williams, P. W. Hunt, R. Hoh, S. L. Stramer, J. M. Linnen, J. M. McCune, et al. 2009. Evidence for persistent low-level viremia in individuals who control HIV in the absence of antiretroviral therapy. J. Virol. 83: 329-335.
23. + T cells in HIV-infected progressors and long-term nonprogressors. J. Immunol. 165: 1082-1092.
24. Pereyra, F., M. M. Addo, D. E. Kaufmann, Y. Liu, T. Miura, A. Rathod, B. Baker, A. Trocha, R. Rosenberg, E. Mackey, et al. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197: 563-571.
25. + T cells. Blood 107: 4781-4789.
26. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3: 1061-1068.
27. Zimmerli, S. C., A. Harari, C. Cellerai, F. Vallelian, P. A. Bart, and G. Pantaleo. 2005. HIV-1-specific IFN-γ/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc. Natl. Acad. Sci. USA 102: 7239-7244.
28. + T cells: constitutive upregulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood 112: 3679-3687.
29. Schvachsa, N., G. Turk, M. Burgard, D. Dilernia, M. Carobene, M. Pippo, M. Gomez-Carrillo, C. Rouzioux, and H. Salomon. 2007. Examination of real-time PCR for HIV-1 RNA and DNA quantitation in patients infected with HIV-1 BF intersubtype recombinant variants. J. Virol. Methods 140: 222-227.
30. Avettand-Fenoel, V., N. Mahlaoui, M. L. Chaix, C. Milliancourt, M. Burgard, M. Cavazzana-Calvo, C. Rouzioux, and S. Blanche. 2007. Failure of bone marrow transplantation to eradicate HIV reservoir despite efficient HAART. AIDS 21: 776-777.
31. O'Doherty, U., W. J. Swiggard, and M. H. Malim. 2000. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74: 10074-10080.
32. Lacabaratz-Porret, C., A. Urrutia, J. M. Doisne, C. Goujard, C. Deveau, M. Dalod, L. Meyer, C. Rouzioux, J. F. Delfraissy, A. Venet, and M. Sinet. 2003. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J. Infect. Dis. 187: 748-757.
33. + phenotype and memory characteristics after initiation of HAART during acute primary HIV infection. Blood 113: 3209-3217.
34. Avettand-Fenoel, V., T. Prazuck, L. Hocqueloux, A. Melard, C. Michau, R. Kerdraon, E. Agoute, and C. Rouzioux. 2008. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS 22: 1880-1882.
35. Blankson, J. N., J. R. Bailey, S. Thayil, H.-C. Yang, K. Lassen, J. Lai, S. K. Gandhi, J. D. Siliciano, T. M. Williams, and R. F. Siliciano. 2007. Isolation and characterization of replication-competent HIV-1 from a subset of elite suppressors. J. Virol. 81: 2508-2518.
36. Lamine, A., A. Caumont-Sarcos, M. L. Chaix, A. Sáez-Cirión, C. Rouzioux, J. F. Delfraissy, G. Pancino, and O. Lambotte. 2007. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 21: 1043-1045.
37. Miura, T., M. A. Brockman, C. J. Brumme, Z. L. Brumme, J. M. Carlson, F. Pereyra, A. Trocha, M. M. Addo, B. L. Block, A. C. Rothchild, et al. 2008. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J. Virol. 82: 8422-8430.
38. Ferre, A. L., P. W. Hunt, J. W. Critchfield, D. H. Young, M. M. Morris, J. C. Garcia, R. B. Pollard, H. F. Yee, Jr., J. N. Martin, S. G. Deeks, and B. L. Shacklett. 2008. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood Epub ahead of print on Dec. 23, 2008: doi: 10.1182/blood-2008-10-182709.
39. + T-cell activation. J. Virol. 82: 8307-8315.
40. + elite suppressors despite CTL escape mutations. J. Exp. Med. 203: 1357-1369.
41. Chen, H., A. Piechocka-Trocha, T. Miura, M. A. Brockman, B. D. Julg, B. M. Baker, A. C. Rothchild, B. L. Block, A. Schneidewind, T. Koibuchi, et al. 2009. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J. Virol. 83: 3138-3149.
42. + T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 178: 2746-2754.
43. Collins, K. L., B. K. Chen, S. A. Kalams, B. D. Walker, and D. Baltimore. 1998. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391: 397-401.
44. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204: 2473-2485.
45. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29: 1009-1021.
46. + elite suppressors. J. Virol. 83: 88-97.
47. + T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J. Virol. 81: 7725-7731.